ភាគហ៊ុន CytomX លោតបន្ទាប់ពីកិច្ចព្រមព្រៀងព្យាបាលជំងឺមហារីកជាមួយ Pharma Major Regeneron

• CytomX Therapeutics Inc (ផ្សារហ៊ុន NASDAQ: CTMX) និង ឱសថ Regeneron Inc (ផ្សារហ៊ុន NASDAQ: REGN) បានប្រកាសថា ក collaboration and licensing agreement to create conditionally-activated bispecific cancer therapies.

• The collaboration will utilize CytomX’s Probody therapeutic platform and Regeneron’s Veloci-Bi bispecific antibody development platform.

• Under the agreement, Regeneron and CytomX will collaborate on the discovery activities to identify and validate conditionally active bispecific antibodies.

• Regeneron will be responsible for funding preclinical and clinical development and commercialization activities.

• CytomX will receive an upfront payment of $30 million and will be eligible to receive future target nomination payments and preclinical, clinical, and commercial milestones of up to $2 billion.

• CytomX is also eligible to receive tiered global net sales royalties.

• In July, CytomX Therapeutics restructured its business to prioritize internal investments in its emerging preclinical and early clinical pipeline.

• The company cut 40% of its workforce. The changes are expected to extend the company’s cash runway into 2025.

• សកម្មភាពតម្លៃ: CTMX shares are up 24.43% at $1.5057 on the last check Thursday.

មើលអ្វីផ្សេងបន្ថែមទៀតរបស់ Benzinga

កុំខកខានការជូនដំណឹងតាមពេលវេលាជាក់ស្តែងលើភាគហ៊ុនរបស់អ្នក – ចូលរួម ប្រូម៉ាណា ដោយ​ឥតគិតថ្លៃ! សាកល្បងឧបករណ៍ដែលនឹងជួយអ្នកឱ្យវិនិយោគកាន់តែឆ្លាតវៃ លឿនជាងមុន និងប្រសើរជាងមុន។.

© ២០២០ Benzinga.com ។ Benzinga មិនផ្តល់ដំបូន្មានវិនិយោគទេ។ រក្សា​រ​សិទ្ធ​គ្រប់យ៉ាង។